Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sigma-Aldrich and NeuroSurvival Technologies or NST have signed a licensing agreement for a leading marker, developed by NST, for molecular imaging of apoptosis in vitro and in vivo in animals.
Subscribe to our email newsletter
The marker, developed by NST, will be manufactured and marketed by Sigma-Aldrich under the commercial name Apo-TRACE. Apo-TRACE is a member of a family of proprietary small molecules developed by NST that target apoptosis.
Another molecule of the family, ApoSense-PET, is in clinical trials for imaging apoptosis in vivo in humans with PET (positron emitting tomography) and is not part of this agreement. Once the ApoSense-PET molecule also becomes commercially available from NST, apoptosis research in vivo will continue into the clinic and become a valuable biomarker for development and testing of new therapeutic agents. Apo-TRACE is available for purchase from Sigma-Aldrich as of January 2008.